AtriCure, Inc. (ATRC) Earnings Call Transcripts

AtriCure, Inc.'s Latest Earnings Call - June 10, 2026

In Q2 2026, AtriCure, Inc. reported over $600 million in revenue, maintaining its trajectory towards a $1 billion revenue target by 2030. The company emphasized its leadership in the arrhythmia management market, holding over 90% market share. Management reiterated its commitment to double-digit growth, driven by market expansion and innovation. No changes were made to the annual guidance of 12-14% revenue growth, despite a strong start to the year. The focus remains on internal growth catalysts, with no immediate plans for M&A.

Reported metrics

Guidance from management

AtriCure maintained its annual revenue growth guidance of 12-14%, expecting a back-end loaded year with contributions from new product launches.

What management said

Yes. Maybe to put a finer point on it. I say our philosophy is invest growth. I think everything that Mike is describing, we're in a great position. As you said, we are cash flow positive. We are ahead of our LRP relative to the bottom line expectations. And I think we feel comfortable that we can continue to improve profitability, improve margins, continue to generate cash flow, but our investments are geared with a...

What's next? I mean we were bullish that we'll have very positive trial data, which ultimately will expand our market. You're talking about multiplying the market activity for us in cardiac surgery. These are existing customers. doing existing procedures with existing devices. It gives us an automatic start to go and attack these markets in full. I think Mike said it really well at the beginning. When you think abou...

What analysts pressed on

Analysts expressed concerns about competitive pressures from companies like Medtronic and the impact on market share. Questions also focused on the sustainability of growth rates and the strategic balance between profitability and reinvestment.

Main topics on the call

• Revenue Growth and Market Leadership — AtriCure projects over $600 million in revenue for 2026, aiming for $1 billion by 2030. CEO Michael Carrel stated, 'we are #1 in the markets that we serve,' with over 90% market share in arrhythmia management.
• Vision 2030 and Market Expansion — The company aims to triple its market size with the Box A trial, targeting a $10 billion global market. Carrel noted, 'every 1 of those patients can benefit from an ablation,' indicating significant growth potential.
• Profitability and Cash Flow — AtriCure is now profitable and cash flow positive, reducing the need for external financing. Carrel emphasized, 'we are making money, driving cash now,' highlighting financial stability.
• Competitive Landscape — Despite new entrants like Medtronic, AtriCure maintains a competitive edge through innovation and clinical evidence. Carrel stated, 'we will innovate evidence them and out support the team out in the field.'

Read the full AtriCure, Inc. transcript (June 10, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 49 AtriCure, Inc. earnings call transcripts on record, spanning January 16, 2020 to July 23, 2026. Based on this history, AtriCure, Inc. reports quarterly. The most recent call on file is dated July 23, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

ATRC

Exchange

NasdaqGM

Country

US

Sector

Health Care

Industry

Health Care Equipment and Supplies

Calls on record

49

First call

January 16, 2020

Most recent

July 23, 2026

Reporting cadence

quarterly